ECOR - NASDAQ
electroCore, Inc.
$9.75
-1.1%electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
At a Glance
Live SnapshotelectroCore, Inc. Management Team
Daniel S. Goldberger
Chief Executive Officer & Director
Compensation
$1,132,585
Joshua S. Lev
Chief Financial Officer
Compensation
$605,102
Peter S. Staats
Chief Medical Officer
Compensation
$238,415
Amanda Yanuklis
Chief of Staff
Thomas J. Errico
Founder & Independent Chairman
Compensation
$67,500
Donald Melnikoff
Senior Vice President of Engineering, Regulatory & Compliance
Manuel A. Marques
Senior Vice President of Operations
Kelly Benning
Senior Vice President of Truvaga
Andy Brown
Vice President & Corporate Controller
Mitch Deshon
Vice President of Global Sales & Business Development
electroCore, Inc. Insider Positioning
During the last 12 months, insiders have purchased $136K and sold $202K worth of ECOR shares, resulting in $66K of net selling activity.
3 Months
10.0K
59.85K
25.7K
176.26K
-116K
-$116K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
1.0K
4.84K
4.7K
26.01K
-21K
-$21K
9-12 Months
16.0K
71.28K
0
0.00
+71K
+$71K
Top Buyers
Errico Thomas J.
Director
$127K
Goldberger Daniel S
Director, Officer: Chief Executive Officer
$9K
Top Sellers
Lev Joshua S.
Officer: Cfo And Interim President
$106K
Goldberger Daniel S
Other: Former Officer And Director
$97K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $66K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Negative recent trend with net selling. Insiders have reduced positions in recent months, which could signal caution.
Insider Participation
2 insider buyers and 2 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
ECOR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | July 17, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | July 17, 2024 | September 03, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 05, 2023 | August 04, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | December 23, 2022 | February 13, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 11, 2022 | December 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 26, 2021 | April 26, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 27, 2020 | June 12, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 07, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.